| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 36.718 | 79.084 | 76.605 | 56.742 | 57.985 | 69.687 | 92.116 | 121.551 | 132.014 | 153.097 |
| Total Income - EUR | 37.398 | 80.085 | 77.674 | 58.136 | 58.029 | 69.724 | 92.154 | 121.588 | 132.174 | 153.103 |
| Total Expenses - EUR | 36.153 | 79.083 | 76.687 | 63.145 | 58.292 | 66.330 | 90.390 | 126.729 | 138.157 | 165.425 |
| Gross Profit/Loss - EUR | 1.245 | 1.002 | 987 | -5.009 | -264 | 3.393 | 1.764 | -5.141 | -5.983 | -12.322 |
| Net Profit/Loss - EUR | 137 | 210 | 220 | -5.577 | -844 | 2.896 | 842 | -6.358 | -7.309 | -12.322 |
| Employees | 2 | 2 | 4 | 4 | 2 | 2 | 2 | 3 | 3 | 4 |
Check the financial reports for the company - Miralexfarma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 380 | 202 | 43 | 0 | 56 | 0 | 20.311 | 15.601 | 8.527 | 3.565 |
| Current Assets | 19.522 | 18.221 | 22.801 | 14.529 | 20.943 | 24.609 | 32.301 | 31.295 | 25.997 | 28.132 |
| Inventories | 6.941 | 6.256 | 6.690 | 5.508 | 9.816 | 9.338 | 12.705 | 11.565 | 11.162 | 15.843 |
| Receivables | 10.728 | 5.531 | 15.862 | 8.971 | 9.243 | 13.924 | 17.477 | 18.874 | 13.233 | 10.886 |
| Cash | 1.854 | 6.433 | 250 | 50 | 1.885 | 1.347 | 2.120 | 856 | 1.602 | 1.402 |
| Shareholders Funds | 182 | 390 | 397 | -5.403 | -6.142 | -3.129 | -2.218 | -8.583 | -15.865 | -28.098 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 19.752 | 18.033 | 22.447 | 19.932 | 27.142 | 27.738 | 55.054 | 55.529 | 50.957 | 60.429 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Miralexfarma S.r.l.